A new trading day began on Monday, with IGC Pharma Inc (AMEX: IGC) stock price down -4.42% from the previous day of trading, before settling in for the closing price of $0.33. IGC’s price has ranged from $0.26 to $0.91 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 4.59%. Meanwhile, its annual earnings per share averaged 54.55%. With a float of $55.48 million, this company’s outstanding shares have now reached $78.20 million.
Let’s determine the extent of company efficiency that accounts for 67 employees. In terms of profitability, gross margin is 51.46%, operating margin of -663.75%, and the pretax margin is -712.7%.
IGC Pharma Inc (IGC) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of IGC Pharma Inc is 30.37%, while institutional ownership is 3.56%. The most recent insider transaction that took place on Sep 25 ’24, was worth 200,000. In this transaction Director of this company bought 588,235 shares at a rate of $0.34, taking the stock ownership to the 942,402 shares. Before that another transaction happened on Aug 12 ’24, when Company’s Director proposed sale 200,000 for $0.39, making the entire transaction worth $78,200.
IGC Pharma Inc (IGC) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 54.55% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.29% during the next five years compared to -13.79% drop over the previous five years of trading.
IGC Pharma Inc (AMEX: IGC) Trading Performance Indicators
Here are IGC Pharma Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.59. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 20.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.12, a number that is poised to hit -0.02 in the next quarter and is forecasted to reach -0.10 in one year’s time.
Technical Analysis of IGC Pharma Inc (IGC)
Looking closely at IGC Pharma Inc (AMEX: IGC), its last 5-days average volume was 0.6 million, which is a jump from its year-to-date volume of 0.42 million. As of the previous 9 days, the stock’s Stochastic %D was 69.50%. Additionally, its Average True Range was 0.02.
During the past 100 days, IGC Pharma Inc’s (IGC) raw stochastic average was set at 34.99%, which indicates a significant decrease from 61.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.29% in the past 14 days, which was higher than the 50.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3174, while its 200-day Moving Average is $0.3770. However, in the short run, IGC Pharma Inc’s stock first resistance to watch stands at $0.3360. Second resistance stands at $0.3520. The third major resistance level sits at $0.3640. If the price goes on to break the first support level at $0.3080, it is likely to go to the next support level at $0.2960. Should the price break the second support level, the third support level stands at $0.2800.
IGC Pharma Inc (AMEX: IGC) Key Stats
With a market capitalization of 25.50 million, the company has a total of 79,685K Shares Outstanding. Currently, annual sales are 1,350 K while annual income is -13,000 K. The company’s previous quarter sales were 260 K while its latest quarter income was -1,830 K.
